- Home
- Automated
- List of product information
- NOLVADEX-D TABLET 20 MG [SIN00796P]
NOLVADEX-D TABLET 20 MG [SIN00796P]
Active ingredients: NOLVADEX-D TABLET 20 MG
Last updated 26 October 2025
On this page
Product Info
NOLVADEX-D TABLET 20 MG
[SIN00796P]
Product information
Active Ingredient and Strength | TAMOXIFEN CITRATE 30.4 MG EQV TAMOXIFEN - 20 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | ASTRAZENECA UK LTD - UNITED KINGDOM |
Registration Number | SIN00796P |
Licence Holder | ASTRAZENECA SINGAPORE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | L02BA01 |
4.1 Therapeutic indication
NOLVADEX is indicated for the treatment of breast cancer.
4.2 Posology and method of administration
Route of administration: Oral.
Adults (including elderly)
The dosage range is 20 to 40 mg daily, given either in divided doses twice daily or as a single dose once daily.
Use in children
The use of NOLVADEX is not recommended in children, as safety and efficacy have not been established (see Pharmacodynamic and Pharmacokinetics properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
4.3 Contraindications
Pregnancy: NOLVADEX must not be given during pregnancy. Premenopausal patients must be carefully examined before treatment to exclude the possibility of pregnancy (see also Pregnancy and lactation – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
NOLVADEX should not be given to patients who have experienced hypersensitivity to the product or any of its ingredients.